

### Basic information

2022/2819(DEA)

DEA - Delegated acts procedure

Labelling requirements for unauthorised investigational and unauthorised auxiliary medicinal products for human use

Supplementing [2012/0192\(COD\)](#)

#### Subject

4.20.02 Medical research

4.20.02.06 Clinical practice and experiments

4.20.04 Pharmaceutical products and industry

Procedure completed - delegated act enters into force

### Key players

European Parliament

Committee responsible

Rapporteur

Appointed

ENVI

Environment, Public Health and Food Safety

### Key events

Date	Event	Reference	Summary
06/09/2022	Non-legislative basic document published	<a href="#">C(2022)06240</a>	
06/09/2022	Initial period for examining delegated act 2 month(s)		
14/09/2022	Committee referral announced in Parliament		
15/11/2022	Delegated act not objected by Parliament		

### Technical information

Procedure reference	2022/2819(DEA)
Procedure type	DEA - Delegated acts procedure
Procedure subtype	Examination of delegated act
Amendments and repeals	Supplementing <a href="#">2012/0192(COD)</a>
Stage reached in procedure	Procedure completed - delegated act enters into force
Committee dossier	ENVI/9/10019

### Documentation gateway

European Commission

Document type	Reference	Date	Summary
---------------	-----------	------	---------

Non-legislative basic document

[C\(2022\)06240](#)

06/09/2022

--